CI

At a glance

ClinicalIndex Comparison Record
N/AActive· 303 enrolled
Drug / intervention
Anti-HIV Agentsdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02344680
NCT02344680N/AActive
CompareCT.gov

Liver Fibrosis in Zambian HIV-HBV Co-infected Patients: a Long-term Prospective Cohort Study

University of Alabama at Birmingham·observational·Posted Jan 26, 2015·Updated Jun 10, 2025

In Brief

An observational study evaluating Anti-HIV Agents for Human Immunodeficiency Virus and 6 related conditions. Active but no longer recruiting, targeting 303 participants across 1 site.

Detailed Summary

A cohort of adults with HIV-HBV co-infection will be created in Lusaka, Zambia, to describe the short and long-term (up to 10 years of follow-up) HBV and liver outcomes, including the effectiveness of current therapies, and to identify the risk factors for major endpoints of interest, including HCC and HBV functional cure. This cohort will also create a pool of potential participants for in-depth mechanistic studies and clinical trials of novel HBV cure drugs.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHuman Immunodeficiency Virus, HBV, Fibrosis, Liver, Cirrhosis, Liver, Hepatocellular Carcinoma, Hepatitis Delta Virus, Alcoholic Hepatitis
CountriesZambia
CollaboratorsFogarty International Center of the National Institute of Health, National Institutes of Health (NIH)

Timeline

N/AActiveOverdue
201520162017201820192020202120222023202420252026
First PostedJan 26, 2015
Enrollment StartOct 1, 2015
Primary CompletionApr 1, 2026
TodayJul 2, 2026
Enrollment to primary: 10.5 yearsPosted 11.4 years ago

Interventions

Anti-HIV Agentsdrug